|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15291530153115321533153415351536153715381539...15771578» |
- ||| Ukoniq (umbralisib) / TG Therap
New P1 trial, Combination therapy: TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Oct 22, 2015
P1, N=60, Recruiting, Sponsor: TG Therapeutics, Inc.
- ||| sasanlimab (PF-06801591) / Pfizer
New P1 trial, Metastases: A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors (clinicaltrials.gov) - Oct 22, 2015
P1, N=180, Not yet recruiting, Sponsor: Pfizer
- | Qinlock (ripretinib) / Ono Pharma
Metastases: A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies (clinicaltrials.gov) - Oct 22, 2015
P1, N=50, Not yet recruiting, Sponsor: Deciphera Pharmaceuticals LLC
- ||| Ayvakit (avapritinib) / Blueprint Medicines
Enrollment open, Stroma: (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors (clinicaltrials.gov) - Oct 22, 2015
P1, N=60, Recruiting, Sponsor: Blueprint Medicines Corporation
Not yet recruiting --> Recruiting
- Biomarker, New trial: Quantitative Imaging Biomarkers for Sarcoma (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=60, Recruiting, Sponsor: Columbia University
- || imatinib / Generic mfg.
New P3 trial, Stroma: GIGIST: Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index (clinicaltrials.gov) - Oct 22, 2015
P3, N=80, Not yet recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
- | doxorubicin hydrochloride / Generic mfg., dexrazoxane / Generic mfg.
New P2 trial, Head-to-Head, Metastases: Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=73, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||||| Vitrakvi (larotrectinib) / Bayer
New P2 trial, Pan tumor: NAVIGATE: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (clinicaltrials.gov) - Oct 22, 2015
P2, N=151, Recruiting, Sponsor: Loxo Oncology, Inc.
- | Turalio (pexidartinib) / Daiichi Sankyo
New P1/2 trial, Combination therapy: PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=49, Recruiting, Sponsor: Gary Schwartz
- | vocimagene amiretrorepvec/extended release flucytosine (DB107) / Denovo
New P1 trial: A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) (clinicaltrials.gov) - Oct 22, 2015
P1, N=26, Not yet recruiting, Sponsor: Tocagen Inc.
- |||| Rozlytrek (entrectinib) / Roche
Enrollment open, Pan tumor, Metastases: STARTRK-2: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (clinicaltrials.gov) - Oct 22, 2015
P2, N=300, Recruiting, Sponsor: Ignyta, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| indoximod (NLG8189) / Lumos Pharma
Enrollment open: Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors (clinicaltrials.gov) - Oct 22, 2015
P1, N=66, Recruiting, Sponsor: NewLink Genetics Corporation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Xofigo (radium Ra-223 dichloride) / Bayer
Enrollment closed: Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma (clinicaltrials.gov) - Oct 20, 2015
P1/2, N=15, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- trebananib (AMG 386) / Amgen
Trial completion, Surgery, Metastases: Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 20, 2015
P2, N=16, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Metastases: SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas (clinicaltrials.gov) - Oct 15, 2015
P2, N=80, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date, HEOR: Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer (clinicaltrials.gov) - Oct 9, 2015
P=N/A, N=39, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2012
- Ogsiveo (nirogacestat) / SpringWorks Therap
Trial primary completion date: Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis (clinicaltrials.gov) - Oct 7, 2015
P2, N=17, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2012 Trial primary completion date: Oct 2015 --> Dec 2016
- Kisqali (ribociclib) / Novartis
Trial primary completion date: Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma (clinicaltrials.gov) - Oct 7, 2015
P1, N=32, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2015 --> Dec 2016 Trial primary completion date: Jul 2015 --> Mar 2016
- alisertib (MLN8237) / Puma
Enrollment change, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 7, 2015
P2, N=135, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> Mar 2016 N=59 --> 135 | Trial primary completion date: Aug 2015 --> Feb 2016
- |||| selurampanel (BGG492) / Novartis
Trial completion, Enrollment change, Trial primary completion date: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - Oct 7, 2015
P2, N=59, Completed, Sponsor: Novartis Pharmaceuticals
N=59 --> 135 | Trial primary completion date: Aug 2015 --> Feb 2016 Recruiting --> Completed | N=77 --> 59 | Trial primary completion date: Jun 2015 --> Sep 2015
- aldoxorubicin (INNO-206) / ImmunityBio
New trial: Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy (clinicaltrials.gov) - Oct 7, 2015
P=N/A, N=0, Available, Sponsor: CytRx
- perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma (clinicaltrials.gov) - Oct 6, 2015
P1/2, N=92, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=77 --> 59 | Trial primary completion date: Jun 2015 --> Sep 2015 Trial primary completion date: Oct 2015 --> Jul 2016
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
Trial completion, Enrollment change, Trial primary completion date, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 6, 2015
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2015 --> Jul 2016 Active, not recruiting --> Completed | N=60 --> 21 | Trial primary completion date: Sep 2015 --> Jan 2014
- Enrollment status: Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions (clinicaltrials.gov) - Oct 6, 2015
P=N/A, N=29, Enrolling by invitation, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=60 --> 21 | Trial primary completion date: Sep 2015 --> Jan 2014 Recruiting --> Enrolling by invitation
- || Torisel (temsirolimus) / Pfizer
New P3 trial: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (clinicaltrials.gov) - Oct 5, 2015
P3, N=465, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Rozlytrek (entrectinib) / Roche
New P2 trial, Pan tumor, Metastases: STARTRK-2: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (clinicaltrials.gov) - Oct 5, 2015
P2, N=300, Not yet recruiting, Sponsor: Ignyta, Inc.
- Trial primary completion date: Genomic Analysis of Pediatric Bone Tumors (clinicaltrials.gov) - Oct 3, 2015
P=N/A, N=150, Recruiting, Sponsor: Stanford University
Recruiting --> Enrolling by invitation Trial primary completion date: Aug 2014 --> Aug 2016
- mocetinostat (MGCD0103) / Otsuka, BMS
Enrollment open, Trial initiation date, Metastases: SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma (clinicaltrials.gov) - Oct 2, 2015
P2, N=40, Recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Aug 2014 --> Aug 2016 Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Sep 2015
- tasadenoturev (DNX-2401) / DNAtrix
Enrollment open, Enrollment change: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Oct 1, 2015
P1, N=36, Recruiting, Sponsor: DNAtrix, Inc.
Not yet recruiting --> Recruiting | Initiation date: Mar 2015 --> Sep 2015 Active, not recruiting --> Recruiting | N=24 --> 36
- Enrollment closed, Trial primary completion date: Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy (clinicaltrials.gov) - Oct 1, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Recruiting | N=24 --> 36 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Nov 2015
- | Trial completion, Metastases: Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma (clinicaltrials.gov) - Oct 1, 2015
P2, N=34, Completed, Sponsor: University of Wisconsin, Madison
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Nov 2015 Active, not recruiting --> Completed
- || New P3 trial: Preoperative vs Postoperative IMRT for Extremity/Truncal STS (clinicaltrials.gov) - Oct 1, 2015
P3, N=206, Not yet recruiting, Sponsor: Mount Sinai Hospital, Canada
- ||| samrotamab vedotin (ABBV-085) / AbbVie
New P1 trial, Metastases: ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Oct 1, 2015
P1, N=153, Recruiting, Sponsor: AbbVie
- H1299 cell lysate with iscomatrix adjuvant vaccine / National Cancer Institute
Trial primary completion date, IO biomarker: Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum (clinicaltrials.gov) - Sep 30, 2015
P1/2, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Nov 2017 --> Sep 2018
- Enrollment change, Trial primary completion date, Tumor cell: A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation (clinicaltrials.gov) - Sep 30, 2015
P2, N=16, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Trial primary completion date: Nov 2017 --> Sep 2018 N=30 --> 16 | Trial primary completion date: Jan 2013 --> Jun 2009
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015
P1, N=43, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 16 | Trial primary completion date: Jan 2013 --> Jun 2009 Active, not recruiting --> Completed
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment open: CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma (clinicaltrials.gov) - Sep 30, 2015
P2, N=50, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial primary completion date, Metastases: Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (clinicaltrials.gov) - Sep 29, 2015
P2, N=72, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2015 --> Sep 2016
- RG4733 / Roche
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Sep 29, 2015
P1, N=22, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2015 --> Sep 2016 Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013
- cyclophosphamide / Generic mfg., sirolimus / Generic mfg.
Trial completion, Metastases: A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma (clinicaltrials.gov) - Sep 29, 2015
P2, N=49, Completed, Sponsor: University of Michigan Cancer Center
Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013 Active, not recruiting --> Completed
- New P2 trial: SBRT Treatment for Lung Metastasis From Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 28, 2015
P2, N=44, Recruiting, Sponsor: Istituto Clinico Humanitas
- Seprehvir (HSV1716) / Sorrento
Enrollment change: HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors (clinicaltrials.gov) - Sep 25, 2015
P1, N=30, Recruiting, Sponsor: Timothy Cripe
Active, not recruiting --> Completed N=18 --> 30
- Enrollment closed: Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract (clinicaltrials.gov) - Sep 25, 2015
P=N/A, N=6000, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=18 --> 30 Recruiting --> Active, not recruiting
- || Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab Beyond Progression (BBP) (clinicaltrials.gov) - Sep 25, 2015
P2, N=68, Active, not recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Jun 2016
- Trial primary completion date: Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: May 2016 --> Jun 2015
- M032 / The University of Alabama
Trial primary completion date: M032-HSV-1: Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (clinicaltrials.gov) - Sep 24, 2015
P1, N=36, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Trial primary completion date: May 2016 --> Jun 2015 Trial primary completion date: Jul 2015 --> Jul 2016
- Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Takeda, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Trial primary completion date, Metastases: Cabozantinib for Adults With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 24, 2015
P2, N=50, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Sep 2015 --> Jun 2016
- temozolomide / Generic mfg., memantine / Generic mfg., mefloquine / Generic mfg.
Trial primary completion date: Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy (clinicaltrials.gov) - Sep 24, 2015
P1, N=144, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2015 --> Jun 2016 Trial primary completion date: Sep 2016 --> Sep 2017
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Combination therapy: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Sep 24, 2015
P1/2, N=5, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Sep 2016 --> Sep 2017 Trial primary completion date: Aug 2015 --> Nov 2014
- sirolimus / Generic mfg.
Trial primary completion date: A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis (clinicaltrials.gov) - Sep 24, 2015
P1/2, N=15, Recruiting, Sponsor: Maine Medical Center
Trial primary completion date: Aug 2015 --> Nov 2014 Trial primary completion date: Aug 2015 --> Mar 2016